FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
Summary:
The FDA approved zidesamtinib for previously treated ROS1-positive lung cancer, offering a promising targeted therapy with durable responses and strong activity against brain metastases.
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
Summary:
Researchers identified genetic markers linked to CAR-T therapy toxicity, paving the way for safer, more effective personalized cancer immunotherapies.
Sanofi halts development of troubled immune drug in eczema
Summary:
Sanofi has discontinued development of its next-generation eczema drug after efficacy and safety concerns, underscoring the challenges of finding a successor to Dupixent.
CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation
Summary:
The South Korean giant is developing an AI platform to automate cell therapy regulatory documentation, aiming to accelerate approvals and improve efficiency across drug development.
J.P. Morgan report shows biopharma, medtech investment strong in H1 2026
Summary:
Biopharma and medtech investment remained strong in early 2026, with investors favoring later-stage innovations and milestone-based partnerships to reduce development risk.
